RuiYi Signs On New Partners To Develop Anti-IL6 mAb In China
This article was originally published in PharmAsia News
Executive Summary
The China-U.S. hybrid signs on Shanghai-based Genor Biopharma in a co-development deal and contract manufacturer CMC Biologics to develop a cell line for RYI-008 for global manufacturing.